# FDA Inspection 1191290 - Octapharma Plasma Inc - November 17, 2022

Source: https://www.keypedia.com/records/fda_inspections/octapharma-plasma-inc/b5b1fb52-519b-4f2a-8c3d-52ed054c4125
Source feed: FDA_Inspections

> FDA Inspection 1191290 for Octapharma Plasma Inc on November 17, 2022. Classification: No Action Indicated (NAI).

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 1191290
- Company Name: Octapharma Plasma Inc
- Inspection Date: 2022-11-17
- Classification: No Action Indicated (NAI)
- Project Area: Blood and Blood Products
- Product Type: Biologics
- Office Name: Center for Biologics Evaluation and Research

## Related Documents

- [FDA Inspection 1042874 - 2018-01-26](https://www.keypedia.com/records/fda_inspections/octapharma-plasma-inc/43350969-0f02-44f0-b500-bd48ed51e2e2)
- [FDA Inspection 908697 - 2014-12-31](https://www.keypedia.com/records/fda_inspections/octapharma-plasma-inc/197ee311-2d0d-4f94-8a69-8243129d1eda)
- [FDA Inspection 804201 - 2012-10-17](https://www.keypedia.com/records/fda_inspections/octapharma-plasma-inc/b8e6e571-b841-42b3-b4c0-8836a98db1eb)
- [FDA Inspection 744338 - 2011-09-13](https://www.keypedia.com/records/fda_inspections/octapharma-plasma-inc/948625bb-45af-495f-8874-c10f6de30516)

Company: https://www.keypedia.com/companies/octapharma-plasma-inc/a5c33d9b-1531-4e46-adee-9e35916d438b

Office: https://www.keypedia.com/offices/center-for-biologics-evaluation-and-research/dd9e8ea7-6f04-4ed1-b0d7-e7e6b264570d